MedTrace Logo

Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System

NCT00698425 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2010-08-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of a single iontophoretic dose of buffered solution administered through the EyeGate® II Drug Delivery System in healthy adult human volunteers.

Conditions

  • Healthy

Interventions

OTHER

EyeGate II® Drug Delivery System

Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System

DRUG

Citrate buffer

Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System

Sponsors & Collaborators

  • Eyegate Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Manjoo Reddy, MS · St Johns Medical College Hospital, Bangalore, India

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00698425 on ClinicalTrials.gov